Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Rosana Kapeller-Libermann net worth and biography

Rosana Kapeller-Libermann Biography and Net Worth

Director of Schrödinger

Rosana Kapeller-Libermann is CEO and President of ROME Therapeutics and a Fellow at GV. She brings over 25 years of scientific leadership and entrepreneurial experience to her role.

Prior to co-founding ROME, Rosana was the founding Chief Scientific Officer of Nimbus Therapeutics, where she led the company’s initiative to apply advanced computational technologies to the design and development of novel therapeutics. During her tenure at Nimbus, she assembled a strong scientific team that validated the company’s platform and advanced multiple promising programs. Before Nimbus, Rosana served as VP of Research at Aileron Therapeutics. Early in her career, she worked at Millennium Pharmaceuticals, and consulted for Third Rock Ventures and Atlas Venture.

Rosana is a member of the board of directors of Cedilla Therapeutics and of the Blavatnik fellowship key advisory board. She earned her M.D. from Universidade do Estado do Rio de Janeiro in Brazil and her Ph.D. in Molecular and Cellular Biology from Tufts University.

What is Rosana Kapeller-Libermann's net worth?: The estimated net worth of Rosana Kapeller-Libermann is at least $23,970.00 as of June 7th, 2021. Dr. Kapeller-Libermann owns 1,000 shares of Schrödinger stock worth more than $23,970 as of April 27th. This net worth evaluation does not reflect any other investments that Dr. Kapeller-Libermann may own. Learn More about Rosana Kapeller-Libermann's net worth.
How do I contact Rosana Kapeller-Libermann?: The corporate mailing address for Dr. Kapeller-Libermann and other Schrödinger executives is 120 WEST 45TH STREET 17TH FLOOR, NEW YORK NY, 10036. Schrödinger can also be reached via phone at 212-295-5800 and via email at [email protected]. Learn More on Rosana Kapeller-Libermann's contact information.
Has Rosana Kapeller-Libermann been buying or selling shares of Schrödinger?: Rosana Kapeller-Libermann has not been actively trading shares of Schrödinger in the last ninety days. Most recently, Rosana Kapeller-Libermann sold 1,000 shares of the business's stock in a transaction on Monday, June 7th. The shares were sold at an average price of $75.00, for a transaction totalling $75,000.00. Following the completion of the sale, the director now directly owns 1,000 shares of the company's stock, valued at $75,000. Learn More on Rosana Kapeller-Libermann's trading history.
Who are Schrödinger's active insiders?: Schrödinger's insider roster includes Robert Abel (Insider), Karen Akinsanya (Insider), Rosana Kapeller-Libermann (Director), Joel Lebowitz (CFO), David Shaw (Major Shareholder), Yvonne Tran (EVP), and Jorg Weiser (Director). Learn More on Schrödinger's active insiders.
Are insiders buying or selling shares of Schrödinger?: During the last twelve months, insiders at the sold shares 8 times. They sold a total of 48,501 shares worth more than $1,943,224.69. The most recent insider tranaction occured on February, 12th when EVP Yvonne Tran sold 758 shares worth more than $21,443.82. Insiders at Schrödinger own 7.6% of the company. Learn More about insider trades at Schrödinger.
Information on this page was last updated on 2/12/2024.

Rosana Kapeller-Libermann Insider Trading History at Schrödinger

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/7/2021	Sell	1,000	$75.00	$75,000.00	1,000

Rosana Kapeller-Libermann Buying and Selling Activity at Schrödinger

Schrödinger Company Overview

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Today's Range

Now: $23.97

$23.36

$24.27

50 Day Range

MA: $26.77

$23.34

$33.09

2 Week Range

Now: $23.97

$20.76

$59.24

Volume

710,860 shs

Average Volume

847,914 shs

Market Capitalization

$1.73 billion

P/E Ratio

38.05

Dividend Yield

N/A

Beta

1.57

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad